An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer.

An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. Expert Rev Respir Med. 2019 May 23;:1-10 Authors: Procaccio L, Bergamo F, Manai C, Di Antonio V, Fassan M, Zagonel V, Lonardi S, Loupakis F Abstract Introduction: Lung metastases occur in 10-20% of patients with colorectal cancer (CRC). Most of them are treated with palliative intent and have a poor prognosis. Pulmonary metastasectomy may be a curative option for carefully selected patients with 5-year survival rates ranging from 25% to 60%. However, up to 70% of patients develop recurrence after pulmonary metastasectomy. Therefore, the identification of prognostic factors is essential in CRC patients with resectable lung metastases. Areas covered: This review aims at summarizing the actual body of knowledge available on lung metastases from CRC focusing on their clinical, pathological and molecular profile. Moreover, we provide an update on experts' attitudes towards lung metastasectomy, adjuvant or perioperative chemotherapy. Expert opinion: Traditional clinical prognosticators such as the total number of pulmonary metastases, carcinoembryonic antigen (CEA) serum levels before surgery, and presence of lymph node metastases cannot provide reliable criteria to predict survival after lung metastasectomy. Indeed, research efforts have been directed in recent years toward studying the biological characteristics of lung lesions to better define prognosis an...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research

Related Links:

CONCLUSIONS: Penile localization is an extremely rare event and a standard of care has not been elaborated. Treatments are palliative and mainly aimed at pain relief and can comprise chemotherapy, radiotherapy, and surgery. Identification of venous thrombosis as an early sign of involvement could potentially offer patients an earlier diagnosis and a better treatment option. PMID: 31072230 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
In the general population of metastatic colorectal cancer, microsatellite instability, andBRAF‐mutated tumors are more common than previously assumed. Unselected patients with microsatellite instability tumors are very different from patients included in the recent third line immunotherapy trials as most of them areBRAF‐mutated (non‐Lynch), they are older and receive less frequently palliative chemotherapy with limited effects. AbstractBackgroundImmunotherapy for patients with microsatellite ‐instable (MSI‐H) tumors orBRAF‐inhibitors combination treatment forBRAF ‐mutated (mutBRAF) tumors in metastatic colore...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusions The recent, first randomized clinical trial demonstrated overall and progression free survival benefits after SBRT to oligometastatic disease which supports prior retrospective case series (6). The spine is a common site of metastatic bone disease, and as high quality data continue to mature, along with completion of additional randomized clinical trials, it is expected that utility of SBRT to the spine will increase in the future. Spine SBRT is unique due to the requirement of sharp dose falloff to prevent serious neurologic morbidity. With recent advances in radiotherapy planning, robotic patient positionin...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Saeed Nourmohammadi1†, Thazin Nwe Aung2†, Jian Cui2, Jinxin V. Pei1, Michael Lucio De Ieso1, Yuka Harata-Lee2, Zhipeng Qu2, David L. Adelson2* and Andrea J. Yool1* 1Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia 2Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia Traditional Chinese Medicines are promising sources of new agents for controlling cancer metastasis. Compound Kushen Injection (CKI), prepared from medicinal plants Sophora flavescens and Heterosmilax chinensis, disrupts cell cycle...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION:  Old patients can profit from palliative chemotherapy to the same extent as younger ones. PMID: 30965378 [PubMed - in process]
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
Conclusions: Our results showed that the use of chemotherapy in patients with mCRC significantly varies between those with and without children.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
Abstract AIM: To investigate treatment patterns and outcomes of metastatic colorectal cancer (mCRC) patients beyond second progression (PD2) since regorafenib and TAS-102 became available in Hong Kong. METHODS: The clinical records of consecutive mCRC patients who were treated beyond PD2 at Department of Clinical Oncology, Queen Mary Hospital between June 2013 and February 2018, were retrospectively reviewed. RESULTS: Of 176 PD2 patients (76.7% Eastern Cooperative Oncology Group performance status 0/1 and a median follow-up time of 6.6 [range, 0.4-37.2] months), 104 (59%) underwent palliative care only a...
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: Asia Pac J Clin Oncol Source Type: research
AbstractPurpose of ReviewPeritoneal metastases (PM) secondary to colorectal cancer is associated with a poor prognosis. However, cytoreductive surgery with hyperthermia intraperitoneal chemotherapy (CRS/HIPEC) has risen to a more accepted roll in the treatment of peritoneal metastatic disease for various cancers; colorectal cancer is no exception. This review aims to discuss the recent updates and findings for treatment of peritoneal disease secondary to colorectal cancer, especially with respect to individualized patient factors that affect outcomes.Recent FindingsThere are many new studies showing the validity of cytored...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
Conclusions: In modern eras of medical oncology, achieving appropriate resection rates through utilization of state-of-the-art oncological surgery by dedicated experts represents a cornerstone for long-term survival in mCRC.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract BACKGROUND: When treated with molecular targeted agents, patients with unresectable colorectal cancer with right-sided tumors have poorer prognoses than those with left-sided tumors. While primary tumor sidedness may have prognostic value, the prognostic value of tumor sidedness in chemotherapy regimens without targeted therapy is unclear. METHODS: Our study population comprised 678 consecutive patients with unresectable stage IV colorectal cancer who received systemic chemotherapy at the National Cancer Center Hospital in Japan from 1999 to 2015. Patients were stratified by treatment subgroup (with ...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Molecular Biology | Palliative | Respiratory Medicine